Interruption of transmission of Onchocerca volvulus in the Oaxaca focus, Mexico.
All endemic communities of the Oaxaca focus of onchocerciasis in southern Mexico have been treated annually or semi-annually with ivermectin since 1994. In-depth epidemiologic assessments were performed in communities during 2007 and 2008. None of the 52,632 Simulium ochraceum s.l. collected in four sentinel communities was found to contain parasite DNA when tested by polymerase chain reaction-enzyme-linked immunosorbent assay (PCR-ELISA), resulting in an upper bound of the infection rate in the vectors of 0.07/2,000. The prevalence of microfilariae (mf) in the cornea and/or anterior chamber of the eye was also zero (0 of 1,039 residents examined; 95%-UL = 0.35%). Similarly, all 1,164 individuals examined by skin biopsy were mf negative (95%-UL = 0.31%), and sera collected from 3,569 children from 25 communities did not harbor Ov16 IgG4-antibodies (95%-UL = 0.09%). These meet the criteria for absence of morbidity and parasite transmission in the Oaxaca focus. As a result mass treatments with ivermectin were halted in 2009.
Rodríguez-Pérez
Mario A
MA
Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, Tamaulipas, México. drmarodriguez@hotmail.com
Unnasch
Thomas R
TR
Domínguez-Vázquez
Alfredo
A
Morales-Castro
Alba L
AL
Peña-Flores
Graciela P
GP
Orozco-Algarra
María E
ME
Arredondo-Jiménez
Juan I
JI
Richards
Frank
F
Vásquez-Rodríguez
Miguel A
MA
Rendón
Vidal García
VG
D000818:Animals; D000871:Anthelmintics / Q000494:pharmacology*; D018562:Disease Transmission, Infectious; D006801:Humans; D007559:Ivermectin / Q000494:pharmacology*; D008800:Mexico; D017181:Onchocerca volvulus / Q000187:drug effects* / Q000276:immunology; D009855:Onchocerciasis / Q000453:epidemiology / Q000276:immunology / Q000469:parasitology / Q000635:transmission*
D000871:Anthelmintics; D007559:Ivermectin